Short facts

 

API

-

Technology

Digital therapeutics

Indication

Opioid dependence

Development phase

Preclinical

Expected filing with FDA

2021

In-house or partnership

Partnership with GAIA AG

Unmet medical need

The medically assisted treatment of Opioid Use Disorder requires a complete treatment plan, including effective medication, such as Orexo’s commercially available Zubsolv®, and counseling and psychosocial support. The access and quality of counseling and psychosocial support remain one of the main barriers to successful treatment in many areas of the US. Orexo believes that the fully-automated digital therapy can become a valuable addition to existing treatment plans, which will improve patients’ access to treatment and overall treatment outcomes.

The concept

OXD-01 will be powered by Orexo´s partner GAIA’s technology platform broca®, which has been the backbone of more than 70 products and been tested on more than 10,000 patients during clinical trials to date. Based on an artificial intelligence (AI)-expert system, broca® engages users in highly individualized, simulated 1:1 interactions, guiding patients step-by-step towards specific goals and therapeutic targets. This individualization makes GAIA’s products unique and has proven to have a significant positive impact on patients’ treatment outcomes during both multiple clinical trials and actual treatment in various healthcare settings and indications around the world. GAIA’s broca® platform has the flexibility to run the highly individualized products on nearly all web compatible devices, including virtual reality applications.

Related links

About GAIA

https://gaia-group.com/en/

The pressrelease communicating the partnership

https://orexo.com/en/media/press-releases?releaseId=B4A65108A4D7F345

Orexo´s CEO gives his remarks to developing a new digital therapy

https://www.youtube.com/watch?v=zqLeOkWY3jc